REVISE-Diabesity: Randomisation to Endoluminal intestinal liner alone Versus with Incretin analogue in SustainEd Diabesity

Trial Profile

REVISE-Diabesity: Randomisation to Endoluminal intestinal liner alone Versus with Incretin analogue in SustainEd Diabesity

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Diabetes mellitus; Obesity
  • Focus Therapeutic Use
  • Acronyms REVISE-Diabesity
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results of one year safety and efficacy evaluation (n=70) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 25 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 17.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top